Table 3.
Number and timing of DEX implant treatments during the study period
| Parameter | Total population (n = 573) | BRVO (n = 367) | CRVO (n = 206) |
|---|---|---|---|
| Number of DEX implant injections, no. of patients (%) | |||
| 1 | 483 (84.3) | 305 (83.1) | 178 (86.4) |
| 2 | 85 (14.8) | 58 (15.8) | 27 (13.1) |
| 3 | 5 (0.9) | 4 (1.1) | 1 (0.5) |
| For patients who received second injection (n = 90 total): | |||
| Mean days from first to second injection (SD) | 155 (47) | 151 (42) | 164 (56) |
| Range | 59–378 | 59–337 | 92–378 |
| For patients who received third injection (n = 5 total): | |||
| Mean days from first to third injection (SD) | 314 (74) | 324 (82) | 277 (NA) |
| Range | 237–405 | 237–405 | (NA) |
| Mean days from second to third injection (SD) | 166 (61) | 178 (64) | 120 (NA) |
| Range | 105–245 | 105–245 | (NA) |
BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, DEX implant dexamethasone intravitreal implant, NA not applicable, SD standard deviation